<DOC>
	<DOC>NCT00055185</DOC>
	<brief_summary>The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.</brief_summary>
	<brief_title>Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients</brief_title>
	<detailed_description>A 2 arm study involving a series of 3 triweekly doses of PRO 542. One arm will involve patients on a stable dose of anti-retroviral therapy and the other arm will consist of patients not receiving anti-retroviral therapy. Three patients will be enrolled in each arm followed by a safety evaluation. Following the safety evaluation, 3 more patients may be enrolled in each arm. After the first 12 patients, an additional 12 patients may be enrolled pending safety data.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<criteria>Confirmed diagnosis of HIV Patients must be on a stable dose of acceptable antiHIV therapy or receiving no antiHIV therapy for at least four (4) weeks prior to the start of this study HIV1 determination by RNAPCR greater than or equal to 100,000 copies/ml CD4 count &gt;50/cubic mm at screening Patients who have previously received PRO 542 Patients with active, significant infection (other than HIV) not controlled by antibiotics Pregnant or lactating women Patients with an estimated life expectancy of &lt;3 months Patients currently receiving steroids or other immunosuppressive therapy or immunoglobulin therapy except for topical or inhaled steroids Patients with known allergy or hypersensitivity to PRO 542 or immunoglobulin preparations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>